Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2019, Article ID 5601249, 5 pages
https://doi.org/10.1155/2019/5601249
Research Article

Lack of Association between the IL6R Gene Asp358Ala Variant (rs2228145), IL-6 Plasma Levels, and Treatment Resistance in Chilean Schizophrenic Patients Treated with Clozapine

1Departamento de Psiquiatría, Escuela de Medicina, Universidad de Valparaíso, Chile
2Escuela de Química y Farmacia, Facultad de Farmacia, Universidad de Valparaíso, Chile
3Centro de Investigación Farmacopea Chilena, Universidad de Valparaíso, Chile
4Instituto de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Chile
5Departamento de Psiquiatría y Salud Mental Norte, Programa de Genética Humana, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Chile
6Centro Interdisciplinario de Neurociencia de Valparaíso CINV, Universidad de Valparaíso, Chile

Correspondence should be addressed to Alvaro Cavieres; moc.liamg@oravla.sereivac and Pablo R. Moya; lc.vu@ayom.olbap

Received 27 March 2019; Revised 4 June 2019; Accepted 8 June 2019; Published 25 June 2019

Academic Editor: Hugo Schnack

Copyright © 2019 Alvaro Cavieres et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Kirkpatrick and B. J. Miller, “Inflammation and schizophrenia,” Schizophrenia Bulletin, vol. 39, no. 6, pp. 1174–1179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. G. M. Khandaker, L. Cousins, J. Deakin, B. R. Lennox, R. Yolken, and P. B. Jones, “Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment,” The Lancet Psychiatry, vol. 2, no. 3, pp. 258–270, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. K.-S. Na, H.-Y. Jung, and Y.-K. Kim, “The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 48, pp. 277–286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Brown, “Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism,” Developmental Neurobiology, vol. 72, no. 10, pp. 1272–1276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. B. J. Miller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick, “Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects,” Biological Psychiatry, vol. 70, no. 7, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Sekar, A. R. Bialas, H. De Rivera et al., “Schizophrenia risk from complex variation of complement component 4,” Nature, vol. 530, no. 7589, pp. 177–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Tomasik, H. Rahmoune, P. C. Guest, and S. Bahn, “Neuroimmune biomarkers in schizophrenia,” Schizophrenia Research, vol. 176, no. 1, pp. 3–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Luo, H. He, J. Zhang et al., “Changes in serum TNF-alpha, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge,” Comprehensive Psychiatry, vol. 90, pp. 82–87, 2019. View at Publisher · View at Google Scholar
  9. M. Rothaug, C. Becker-Pauly, and S. Rose-John, “The role of interleukin-6 signaling in nervous tissue,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1863, no. 6, pp. 1218–1227, 2016. View at Publisher · View at Google Scholar
  10. C. Garbers, N. Monhasery, S. Aparicio-Siegmund et al., “The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1842, no. 9, pp. 1485–1494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Rafiq, T. M. Frayling, A. Murray et al., “A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects,” Genes & Immunity, vol. 8, no. 7, pp. 552–559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sun, F. Wang, L. Cao et al., “Association between interleukin-6 receptor polymorphism and patients with schizophrenia,” Schizophrenia Research, vol. 102, no. 1-3, pp. 346-347, 2008. View at Publisher · View at Google Scholar
  13. D. Sasayama, C. Wakabayashi, H. Hori et al., “Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients,” Journal of Psychiatric Research, vol. 45, no. 11, pp. 1439–1444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Potvin, E. Stip, A. A. Sepehry, A. Gendron, R. Bah, and E. Kouassi, “Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review,” Biological Psychiatry, vol. 63, no. 8, pp. 801–808, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Paternoster et al., “Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis,” Nature Genetics, vol. 47, no. 12, pp. 1449–1456, 2015. View at Google Scholar
  16. M. A. Ferreira, J. M. Vonk, and H. Baurecht, “Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology,” Nature Genetics, vol. 49, no. 2, pp. 1752–1757, 2017. View at Google Scholar
  17. S. Eyre, J. Bowes, D. Diogo et al., “High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis,” Nature Genetics, vol. 44, no. 12, pp. 1336–1340, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Emilsson, “Co-regulatory networks of human serum proteins link genetics to disease,” Science, vol. 361, no. 6404, pp. 769–773, 2018. View at Publisher · View at Google Scholar
  19. G. Fond, O. Godin, L. Boyer et al., “Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort,” European Archives of Psychiatry and Clinical Neurosciences, 2018. View at Publisher · View at Google Scholar
  20. E. P. Hong and J. W. Park, “Sample size and statistical power calculation in genetic association studies,” Genomics & Informatics, vol. 10, no. 2, pp. 117–122, 2012. View at Publisher · View at Google Scholar
  21. E. E. Lee, S. Hong, A. S. Martin, L. T. Eyler, and D. V. Jeste, “Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables,” The American Journal of Geriatric Psychiatry, vol. 25, no. 1, pp. 50–61, 2017. View at Publisher · View at Google Scholar
  22. M. Maes, H. Y. Meltzer, and E. Bosmans, “Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine,” Acta Psychiatrica Scandinavica, vol. 89, no. 5, pp. 346–351, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Müller, M. Empl, M. Riedel, M. Schwarz, and M. Ackenheil, “Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia,” European Archives of Psychiatry and Clinical Neurosciences, vol. 247, no. 6, pp. 308–313, 1997. View at Publisher · View at Google Scholar · View at Scopus